Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence Score

Abstract

Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptor—positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycle—related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.

Keywords

breast carcinoma Oncotype DX molecular profiling Ki-67 prognosis recurrence score

Get full access to this article

View all access options for this article.

References

Cronin M. , Pho M. , Dutta D. , et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptasepolymerase chain reaction assay. Am J Pathol. 2004;164: 35-42.

Cronin M. , Sangli C. , Liu ML , et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53:1084-1091.

Paik S. , Shak S. , Tang G. , et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.

Sorlie T. , Perou, Tibshirani R , et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.

van't Veer LJ , Dai H. , van de Vijver MJ , et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.

Cobleigh MA , Bitterman P. , Baker J. , et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: high throughout RT-PCR assay of paraffin-embedded tumor tissues [abstract]. Prog Proc Am Soc Clin Oncol. 2003;22:850.

Esteban J. , Baker J. , Cronin M. , et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]. Prog Am Soc Clin Oncol. 2003;22:850.

Paik S. , Shak S. , Tang G. , et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14 [abstract]. Breast Cancer Res Treat. 2003;82:A16.

Paik S. , Tang G. , Shak S. , et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24:3726-34.

10.

Cher ML , Chew K. , Rosenau W. , Carroll PR Cellular proliferation in prostatic adenocarcinomas as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate. 1995;26:87-93.

11.

Gerdes J. , Li L. , Schlueter C. , et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by the monoclonal antibody Ki-67. Am J Pathol. 1991;138: 867-873.

12.

Caly M. , Genin P. , Ghuzlan AA , et al. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. Anticancer Res. 2004;24:3283-3288.

13.

Dowsett M. , Smith IE , Ebbs SR , et al. Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167-170.

14.

Jung SY , Han W. , Lee JW , et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer . Ann Surg Oncol. 2009;16:1112-1121.

15.

Wolff AC , Hammond EH , Schwartz JN , et al. American Society of Clinical Oncology/College of American Pathologist guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.

16.

Habel LA , Shak S. , Jacobs MK , et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8:R25.

17.

Sparano JA The TAILORx trial: individualized options for treatment. Commun Oncol. 2006;3:494-496.

18.

Sparano JA TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7:347-350.

19.

Flanagan M. , Dabbs DJ , Brufsky A. , Beriwal S. , Bhargava R. , et al. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255-1261.

20.

Vo T. , Xing Y. , Meric-Bernstam F. , et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg . 2007;194:527-531.